Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor +/- Docetaxel in KRAS-mutant NSCLC
NCT03095612Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in non-small cell lung cancer (NSCLC), sponsored by UT Southwestern Medical Center. Started Mar 2018; status: terminated.
02
Drugs
selinexor
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03095612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095612.